Literature DB >> 24905548

RIFAMPICIN: an antibiotic with brain protective function.

Burak Yulug1, Lütfü Hanoglu2, Ertugrul Kilic3, Wolf Rüdiger Schabitz4.   

Abstract

Besides its well known antibiotic activity rifampicin exerts multiple brain protective functions in acute cerebral ischemia and chronic neurodegeneration. The present mini-review gives an update of the unique activity of rifampicin in different diseases including Parkinson's disease, meningitis, stroke, Alzheimer's disease and optic nerve injury.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Meningitis; Optic nerve injury; Parkinson's disease; Rifampicin; Stroke

Mesh：

Substances：

Year:  2014        PMID： 24905548     DOI： 10.1016/j.brainresbull.2014.05.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN： 0361-9230            Impact factor:   4.077


  12 in total

Review 1.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

2.  Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.

Authors:  Isabel López-García; Domokos Gerő; Bartosz Szczesny; Petra Szoleczky; Gabor Olah; Katalin Módis; Kangling Zhang; Jungling Gao; Ping Wu; Lawrence C Sowers; Doug DeWitt; Donald S Prough; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2016-11-15       Impact factor: 8.739

3.  Inhibition of aggregation of amyloid-β through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease.

Authors:  Izzeddin Alsalahat; Zubida M Al-Majdoub; Mutasem O Taha; Jill Barber; Harmesh Aojula; Nigel Hodson; Sally Freeman
Journal:  Biochem Biophys Rep       Date:  2021-03-15

Review 4.  New Drugs from Marine Organisms in Alzheimer's Disease.

Authors:  Patrizia Russo; Aliaksei Kisialiou; Palma Lamonaca; Rossana Moroni; Giulia Prinzi; Massimo Fini
Journal:  Mar Drugs       Date:  2015-12-25       Impact factor: 5.118

Review 5.  The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease.

Authors:  Umar H Iqbal; Emma Zeng; Giulio M Pasinetti
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

6.  Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates.

Authors:  Leonardo Acuña; Sabah Hamadat; Natalia S Corbalán; Florencia González-Lizárraga; Mauricio Dos-Santos-Pereira; Jérémy Rocca; Julia Sepúlveda Díaz; Elaine Del-Bel; Dulce Papy-García; Rosana N Chehín; Patrick P Michel; Rita Raisman-Vozari
Journal:  Cells       Date:  2019-07-25       Impact factor: 6.600

7.  Rifampicin attenuates experimental autoimmune encephalomyelitis by inhibiting pathogenic Th17 cells responses.

Authors:  Ke Ma; Xi Chen; Jia-Cheng Chen; Ying Wang; Xi-Meng Zhang; Fan Huang; Jun-Jiong Zheng; Xiong Chen; Wei Yu; Ke-Ling Cheng; Yan-Qing Feng; Huai-Yu Gu
Journal:  J Neurochem       Date:  2016-11-29       Impact factor: 5.372

Review 8.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

Review 9.  Insights into the roles of bacterial infection and antibiotics in Parkinson's disease.

Authors:  Shuo Sheng; Shuo Zhao; Feng Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

10.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.